drugset
drugset / Trial / NCT06765668

A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease

NCT06765668 ↗

Phase 4 Recruiting 220 enrolled Impax Laboratories, LLC Amneal Pharmaceuticals, LLC · collab
NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to evaluate efficacy and safety of CREXONT under real world conditions in participants with Parkinson disease (PD).

Timeline

Start
2025-02-12
Primary completion
2025-11
Completion
2026-08-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbidopa Unknown 35 mg Oral
Subject Carbidopa Unknown 52.5 mg Oral
Subject Carbidopa Unknown 70 mg Oral
Subject Carbidopa Unknown 87.5 mg Oral
Subject Levodopa Small molecule 140 mg Oral
Subject Levodopa Small molecule 210 mg Oral
Subject Levodopa Small molecule 280 mg Oral
Subject Levodopa Small molecule 350 mg Oral

Indications

Parkinson disease